



Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II

June 16, 2020

HENDERSON, Nev.--(BUSINESS WIRE)--Jun. 16, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent model. The abstract titled "Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy" will be part of the Special Populations, Survivorship, Outcomes, and Supportive Care session at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held June 22-24, 2020. Full details of the poster are as follows:

Abstract Title: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy

Authors: Yu-Yon Kim., et al.

Session: Special Populations, Survivorship, Outcomes, and Supportive Care

Date and Time: June 22, 2020, 9 a.m. - 6 p.m. EDT

Poster Number: 2044 / 22

Location: Access to the AACR Virtual Annual Meeting II will be free to everyone. While access will be free, attendees will be required to register to view the meeting. [Registration for the meeting is available through the myAACR portal.](#)

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2020 Spectrum Pharmaceuticals, Inc. All Rights Reserved

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200616005276/en/): <https://www.businesswire.com/news/home/20200616005276/en/>

Robert Uhl
Managing Director, Westwicke ICR
858.356.5932
robert.uhl@westwicke.com

Kurt Gustafson
Chief Financial Officer
949.788.6700
InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals, Inc.